Programme Guide · Programme Guide. THERANOSTICS Precision Oncology 3 WELCOME MESSAGE radioisotopes...

Looking Back and Moving Forward: International Symposiumon the Occasion of the 20th Anniversary of Molecular Radiotherapyat Zentralklinik Bad Berka and Inauguration of the ICPO Foundation

INTERNATIONAL SYMPOSIUMTHERANOSTICS/PRECISION ONCOLOGY

12 - 14 DECEMBER 2019BAD BERKA, GERMANY

Programme Guide

THERANOSTICS / Precision Oncology 3

WELCOME MESSAGE

[email protected] www.icpo.foundation

ICPO Foundation

International Centers for Precision Oncology

To support science, technology development and networking in the

field of Precision Oncology!

Donate ICPO Foundation: Bank: BW-Bank, IBAN: DE 54 6005 0101 0405 2216 28, BIC: SOLADEST600

Prof. Dr. Richard P. Baum

Precision Oncology is a tool to decode the channels of interaction, translation and trans-duction of information between genes, cells, microenvironment and macro-environment at tissue, organ and organ system level, with the goal of integrating them in disease manage-ment strategies. Nuclear medicine indeed is the first proponent of the basic principles of precision oncology, using radioactive iodine for the treatment of hyperthyroidism (Saul Hertz 1941) and of thyroid cancer (Samuel Seidlin 1942). Encouraged by the ‘magic bul-let’ concept of Paul Ehrlich (1899), the hybri-doma technology (Köhler and Milstein 1975) enabled the production of monoclonal antibo-dies in unlimited quantities, which has further revolutionized the concept of diagnosis and therapy in nuclear medicine. Major break-throughs were made in radionuclide produc-tion using generators. In 2011 we organized the first World Congress on Gallium-68 and PRRT (with participants from 56 countries), which took place in Chandigarh, Baltimore, Melbourne, and Jeju over the last years. The utility of positron emission tomography was recognized early by the administration of Zentralklinik Bad Berka (ZBB), and in 1997, the first PET scanner, was installed. In paral-lel, ZBB obtained its first cyclotron and GMP-certified radiopharmacy. The very first patient was treated in Germany by peptide receptor radionuclide therapy (PRRT) in July 1997 at Frankfurt University Hospital using Y-90 DO-TATOC – produced by Helmut Mäcke in Basel.

In February 1999, the boy was also the first patient at ZBB to undergo intra-arterial PRRT which relieved his paraplegia completely. In 1999, the ZBB isotope ward was opened, be-coming the largest molecular radiotherapy ward in Europe. In the last 20 years, more than 6200 PRRT in over 1600 patients from across the globe have been performed. In addition, the world’s first Lu-177 PSMA radio-ligand therapy of prostate cancer was per-formed at ZBB early in 2013, and since then, more than 1300 treatment cycles (>300 pati-ents) have been administered. During the last twenty years, innovative new radiopharma-ceuticals, radionuclide generators and novel radioisotopes (e.g. Tb-152 and Tb-161), obtai-ned from leading radiochemists and industry have helped cancer patients devoid of hope. In 2016, we opened our new state-of-the-art radiopharmaceutical building. The ICPO Foundation was established in March 2019, with the main objective of fos-tering the communication between patients, medical experts, industry and governments to build an international community bringing Precision Oncology, Targeted Isotope Ima-ging and Therapy to the growing numbers of patients worldwide. The key mission of the ICPO is to establish a global network of In-ternational Centers for Precision Oncology, based on Best Practice Standards, Methods and Qualifications and to foster global ex-pansion and the communication in between the centers.The ICPO Foundation is very honored to be able to celebrate its official inauguration to-gether with the 20th Anniversary of Targe-ted Isotope Therapy in Bad Berka.Precision oncology is the future of cancer care and your active involvement and parti-cipation will make this symposium a success story to the benefit of our patients.„Ægroti Salus Suprema Lex” −The Benefit of the Patient is the Highest Law.

THERANOSTICS / Precision Oncology4 THERANOSTICS / Precision Oncology 5

INVITED SPEAKERSGENERAL INFORMATION

Congress Venue

Kultur- und Kongresshaus »Station 33«Zentralklinik Bad Berka GmbH Robert-Koch-Allee 999437 Bad Berka, Germany

Local Organizing Committee

Harshad Kulkarni, Bad Berka (Germany)

Julitta Rück-Baum, Hargesheim (Germany)

Sabine Seifert, Bad Berka (Germany)

Official Congress Websitewww.precision-oncology.info

Organizer

ICPO Holding gGmbHBanneggstraße 5788214 Ravensburg, Germany

Registration desk will be open:

Thursday, December 12, 2019 16:30 – 18:00

Friday, December 13, 2019 08:00 – 17:30

Saturday, December 14, 2019 07:30 – 16:30

Registration, Accomodation and Trade Exhibition

Kongress- und Kulturmanagement GmbHRießnerstraße 12 B99427 Weimar, Germanyfon: +49 3643 2468-0 e-Mail: [email protected] e-Mail: [email protected] website: www.kukm.de

Baum, Richard P. Bad Berka (Germany)

Beyer, Gerd Geneve (Switzerland)

Bodei, Lisa New York (USA)

Buck, Oliver Bayerisch Gmain (Germany)

Carrio, Ignasi Barcelona (Spain)

Chang, Anthony Grand Rapids (USA)

Cherry, Simon Davis (USA)

Cremonesi, Marta Milano (Italy)

Czernin, Johannes Los Angeles (USA)

Frilling, Andrea London (UK)

Giammarile, Francesco Vienna (Austria)

Giesel, Frederik Heidelberg (Germany)

Grabowski, Patricia Berlin (Germany)

Griewing, Bernd Bad Neustadt (Germany)

Hommann, Merten Bad Berka (Germany)

Jadvar, Hossein Los Angeles (USA)

Kämmerer, Daniel Bad Berka (Germany)

Klaphake, Axel Bonn (Germany)

Klöppel, Günter Munich (Germany)

Kulkarni, Harshad Bad Berka (Germany)

Larson, Steven New York (USA)

Mailman, Josh San Francisco (USA)

Maina-Nock, Theodosia Athens (Greece)

Modlin, Irvin New Haven (USA)

Müller, Cristina Villigen (Switzerland)

Müller, Dirk Bad Berka (Germany)

Paganelli, Giovanni Meldola (Italy)

Pavel, Marianne Erlangen (Germany)

Pomper, Martin Baltimore (USA)

Prasad, Vikas Ulm (Germany)

Rösch, Frank Mainz (Germany)

Sathekge, Mike Pretoria (South Africa)


INVITED SPEAKERS CHAIRPERSONS

Amaral, Horacio Santiago de Chile (Chile)

Bernal Trujillo, Patricia Isabel Bogota (Columbia)

Biersack, Hans Jürgen Bonn (Germany)

Bouterfa, Hakim Würzburg (Germany)

Buscombe, John Cambridge (UK)

Chatal, Jean-Francois Nantes (France)

Choudhary, Partha Delhi (India)

Corstens, Frans Nijmegen (The Netherlands)

Eiber, Matthias Munich (Germany)

Essler, Markus Bonn (Germany)

Fischer, Manfred Kassel (Germany)

Herrman, Ken Essen (Germany)

Hörsch, Dieter Bad Berka (Germany)


Jeong, Jae Min Seoul (South Korea)

Kairemo, Kalevi Helsinki (Finland)

Kinuya, Seigo Kanazawa (Japan)

Kopka, Klaus Dresden (Germany)

Kramer, Vasko Santiago de Chile (Chile)

Kreißl, Michael Magdeburg (Germany)

Liu, Chen Beijing (China)

Luster, Markus Marburg (Germany)

Mäcke, Helmut Freiburg (Germany)

Öberg, Kjell Uppsala (Sweden)

Prior, John Lausanne (Switzerland)

Scheidhauer, Klemens Munich (Germany)

Thakur, Madhukar Philadelphia (USA)

van der Meulen, Nicholas Philip Villigen (Switzerland)

Wolin, Edward New York (USA)

Yang, Zhi Beijing (China)

Schuchardt, Christiane Bad Berka (Germany)

Singh, Aviral Bad Berka (Germany)

Smerling, Christiane Berlin (Germany)

Talbot, Jean-Noël Paris (France)

Türler, Andreas Berne (Switzerland)

Turner, J. Harvey Perth (Australia)

Vallabhajosula, Shankar New York (USA)

van Echteld, Cees Dresden (Germany)

Virgolini, Irene Vienna (Austria)

Wahl, Richard St. Louis (USA)

Weber, Wolfgang Munich (Germany)

Wild, Damian Basel (Switzerland)

Wirtz, Ralph Cologne (Germany)

Zhang, Jingjing Philadelphia (USA)


INTERNATIONAL SCIENTIFIC BOARD

Goldenberg, David Belleville (USA)

Goldsmith, Stanley J. New York (USA)

Grabowski, Patricia Berlin (Germany)

Griewing, Bernd Bad Neustadt (Germany)

Hacker, Marcus Vienna (Austria)

Haug, Alexander Vienna (Austria)

Heidari, Pedram Boston (USA)

Hellwig Dirk Regensburg (Germany)

Herrmann, Ken Essen (Germany)

Hertel, Andreas Fulda (Germany)

Hommann, Merten Bad Berka (Germany)

Hörsch, Dieter Bad Berka (Germany)


Jeong, Jae Min Seoul (South Korea)

de Jong, Marion Rotterdam (The Netherlands)

Kairemo, Kalevi Helsinki (Finland)

Kämmerer, Daniel Bad Berka (Germany)

Kang, Keon W. Seoul (Korea)

Kinuya, Seigo Kanazawa (Japan)

Klaphake, Axel Bonn (Germany)

Klöppel, Günter Munich (Germany)

Kluge, Andreas Dresden (Germany)

Koester, Ulli Grenoble (France)

Kopka, Klaus Dresden (Germany)

Kramer, Vasko Santiago de Chile (Chile)

Krause, Bernd Rostock (Germany)

Kreißl, Michael Magdeburg (Germany)

Kulkarni, Harshad Bad Berka (Germany)

Langsteger, Werner Linz (Austria)

Larson, Steven New York (USA)

Lee, Sze Ting Sydney (Australia)

Lele, Vikram Mumbai (India)

INTERNATIONAL SCIENTIFIC BOARD

Agolti, Mariela Parana (Argentina)

Ahmadzadehfar, Hojjat Bonn (Germany)

Amaral, Horacio Santiago de Chile (Chile)

Bander, Neil H. New York (USA)

Bandong, Irene Quezon City (Philippines)

Baum, Richard P. Bad Berka (Germany)

Behrenbruch, Christian Melbourne (Australia)

Bernal Trujillo, Isabel Patricia Bogota (Columbia)

Beyer, Gerd Geneve (Switzerland)

Biersack, Hans Jürgen Bonn (Germany)

Blaickner, Matthias Vienna (Austria)

Bodei, Lisa New York (USA)

Bouterfa, Hakim Wuerzburg (Germany)

Buck, Oliver Bayerisch Gmain (Germany)

Buscombe, John Cambridge (UK)

Carrio, Ignasi Barcelona (Spain)

Chang, Anthony Grand Rapids (USA)

Chatal, Jean-Francois Nantes (France)

Cherry, Simon Davis (USA)

Choudhary, Partha Delhi (India)

Corstens, Frans Nijmegen (The Netherlands)

Cremonesi, Marta Milano (Italy)

Czernin, Johannes Los Angeles (USA)

Delpassand, Ebrahim S. Houston (USA)

Dierckx, Rudi A. Groningen (The Netherlands)

Eiber, Matthias Munich (Germany)

Essler, Markus Bonn (Germany)

Fischer, Manfred Kassel (Germany)

Frangos, Savvas Lemesos (Cyprus)

Frilling, Andrea London (UK)

Giammarile, Francesco Vienna (Austria)

Giesel, Frederik Heidelberg (Germany)


INTERNATIONAL SCIENTIFIC BOARD INTERNATIONAL SCIENTIFIC BOARD

Lenzo, Nat Sydney (Australia)

Liu, Chen Beijing (China)

Luster, Markus Marburg (Germany)

Mäcke, Helmut Freiburg (Germany)

Mailman, Josh San Francisco (USA)

Maina-Nock, Theodosia Athens (Greece)

Marx, Sebastian Munich (Germany)

McEwan, Sandy Edmonton (Canada)

Modlin, Irvin New Haven (USA)

Morris, Michael New York (USA)

Müller, Cristina Villigen (Switzerland)

Müller, Dirk Bad Berka (Germany)

Niesen, Andreas Hannover (Germany)

Öberg, Kjell Uppsala (Sweden)

O‘Dorisio, Sue Iowa (USA)

O‘Dorisio, Thomas Iowa (USA)

Oliva, Juan P. Habana (Cuba)

Paez, Diana Vienna (Austria)

Paganelli, Giovanni Meldola (Italy)

Pavel, Marianne Erlangen (Germany)

Pienta, Kenneth Baltimore (USA)

Pomper, Martin Baltimore (USA)

Prasad, Vikas Ulm (Germany)

Prior, John Lausanne (Switzerland)

Rahbar, Kambiz Muenster (Germany)

Reubi, Jean-Claude Berne (Swizerland)

Rösch, Frank Mainz (Germany)

Salavati, Ali Minneapolis (USA)

Sartor, Oliver New Orleans (USA)

Sathekge, Mike Pretoria (South Africa)

Satz, Stanley Boca Raton (USA)

Scheidhauer, Klemens Munich (Germany)

Schelbert, Heinrich Los Angeles (USA)

Scher, Howard I. New York (USA)

Schmidt, Matthias Cologne (Germany)

Schöder, Heiko New York (USA)

Schuchardt, Christiane Bad Berka (Germany)

Schultz, Michael Iowa (USA)

Scott, Andrew Sydney (Australia)

Shi, Kuangyu Berne (Switzerland)

Singh, Aviral Bad Berka (Germany)

Singh, Baljinder Chandigarh (India)

Siraj, Qaisar (Kuwait)

Smerling, Christiane Berlin (Germany)

Tagawa, Scott T. New York (USA)

Talbot, Jean-Noël Paris (France)

Thakur, Madhukar Philadelphia (USA)

Türler, Andreas Berne (Switzerland)

Turner, J. Harvey Perth (Australia)

Vallabhajosula, Shankar New York (USA)

van der Meulen, Nicholas Philip Villigen (Switzerland)

van Echteld, Cees Dresden (Germany)

Virgolini, Irene Vienna (Austria)

von Eyben, Finn Edler Odense (Denmark)

Wahl, Richard St. Louis (USA)

Weber, Wolfgang Munich (Germany)

Wiedenmann, Bertram Berlin (Germany)

Wild, Damian Basel (Switzerland)

Wirtz, Ralph Cologne (Germany)

Wolin, Edward New York (USA)

Yang, Zhi Beijing (China)

Zhang, Jingjing Philadelphia (USA)

Zhernosek Konstantin Munich (Germany)

Zhu, Hua Beijing (China)


Sinotau Pharmaceutical Group

Sinotau Pharmaceutical Group is an innovative pharmaceutical company dedicated to R&D, production, distribution and sales of radiopharmaceuticals.Sinotau cooperates with leading radiopharmaceutical companies and research institutes across China, USA and Europe to help develop and introduce novel radiopharmaceutical products to patients in China.Sinotau is focused on products that provide precise diagnosis and accurate treatment in the fields of cardiovascular, neurodegenerative and oncology diseases. To achieve that goal, in addition to licensing promising products from outside partners, Sinotau is also working closely with renowned domestic research institutions and hospitals to develop radiopharmaceutical products in-house.Sinotau looks into the future following the company’s mission “in pursuit of healthier lives”. Through continued investments in R&D, Sinotau is developing a solid portfolio of novel products to improve the quality of life of patients.

Neurodegenerative diseases•Neuraceq•MK6240

Cardiovascular•[18F]-Myozone•CardioPET

Oncology•177Lu-EB-PSMA-617•CTB006•177Lu-Ca199

Our Vision

We are committed to become an integrated solution provider to contribute to the development of China’s radiopharmaceutical sector.

Pipeline

We are focused on products in the fields of cardiovascular, neurodegenerative diseases and oncology.

Contact Us

[email protected]

Address5th Floor, No.9 Building, 8th Life Park, Life Science Park of Zhongguancun,Changping District, Beijing, China, 102206

SCIENTIFIC PROGRAMME

Frid

ayD

ecem

ber

13, 2

019

Thur

sday

Dec

embe

r 12

, 201

9THURSDAY, DECEMBER 12, 2019

16:30 – 18:00 Registration at Zentralklinik Bad Berka

FRIDAY, DECEMBER 13, 2019

08:00 – 17:00 Registration at Zentralklinik Bad Berka

09:00 – 10:15 Opening Ceremony at Zentralklinik Bad Berka (Auditorium Station 33)

Welcome Richard P. Baum (Bad Berka, Germany)

Opening Remarks

Representatives of Rhön-Klinikum AG / Zentralklinik Bad Berka

Bernd Griewing, Bad Neustadt (Germany) / Merten Hommann, Bad Berka (Germany)

International Atomic Energy Agency (IAEA) Francesco Giammarile, Vienna (Austria)

World Association of Radiopharmaceutical and Molecular Therapy (WARMTH)

Irene Virgolini, Vienna (Austria)

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Hossein Jadvar, Los Angeles (USA)

European Association of Nuclear Medicine (EANM) Ignasi Carrio, Barcelona (Spain)

Gesellschaft für Internationale Zusammenarbeit (GIZ) Axel Klaphake, Bonn (Germany)

International Centers for Precision Oncology (ICPO) Oliver Buck (Introduction of International Centers for Precision Oncology)

Bayerisch Gmain (Germany)



FridayD

ecember 13, 2019


Frid

ayD

ecem

ber

13, 2

019

Opening Lecture Richard P. Baum (Bad Berka, Germany)

ON THE HISTORY OF THERANOSTICS – FROM PAUL EHRLICH TO PRECISION ONCOLOGY

10:15 – 12:45 Session I Chairpersons: Jean-François Chatal (Nantes, France)

Hans Jürgen Biersack (Bonn, Germany)

GOETHE’S GENOMIC REFLECTIONS ON BAUM – GRAU IST ALLE THEORIE

Irvin Modlin (New Haven, USA)

FROM ANTIBODIES TO ANTIBODIES – IS THERE A FUTURE FOR RADIOIMMUNOTHERAPY?

Steven Larson (New York, USA)

MAGIC BULLETS FLY AGAIN – THE REVIVAL OF IMMUNOSCINTIGRAPHY AND RADIOIMMUNOTHERAPY

Wolfgang Weber (Munich, Germany)

FAPI: A NEW ONCOLOGICAL IMAGING PROBE Frederik Giesel (Heidelberg, Germany)

Chairpersons: Patricia Isabel Bernal Trujillo (Bogota, Columbia) Matthias Eiber (Munich, Germany)

FROM TARGET TO BAD BERKA – OR WHY 3BP SHOULD REALLY BE 5BP

Christiane Smerling (Berlin, Germany)

MOLECULAR DIAGNOSTICS IN VITRO AND IN VIVO: TARGET SHIFT FROM TUMOR TO STROMA

Ralph Wirtz (Cologne, Germany)

MOLECULAR RADIOTHERAPY: OVERCOMING RESISTANCE Johannes Czernin (Los Angeles, USA)

12:45 – 13:45 Lunch, Visit of Trade Exhibition

13:45 – 15:45 Session II Chairpersons: Klaus Kopka (Dresden, Germany)

Vasko Kramer (Santiago de Chile, Chile)

THE TIMES THEY ARE A – CHANGIN: RADIOMETAL THERANOSTICS FROM 86Y / 90Y TO 68GA / 177LU AND BEYOND

Frank Rösch (Mainz, Germany)

THE BRIDGE FROM RADIOCHEMISTRY OF THE LANTHANIDES TO 225Ac

Gerd Beyer (Geneve, Switzerland)

HIGH-PERFORMANCE RADIOPHARMACY – THE BASE FOR PRECISION ONCOLOGY

Dirk Müller (Bad Berka, Germany)

Chairpersons: Jae Min Jeong (Seoul, South Korea) Nicholas Philip van der Meulen (Villigen, Switzerland)

TERBIUM “SISTERS”: MORE THAN JUST A “SWISS ARMY KNIFE”

Cristina Müller (Villigen, Switzerland)

THERANOSTIC RADIONUCLIDES AND HOW TO PRODUCE THEM

Andreas Türler (Berne, Switzerland)

CONTRIBUTION OF NUCLEAR MEDICINE IN EARLY BREAST CANCER: FROM SENTINEL NODE TO 90Y-BIOTIN RADIOTHERAPY

Giovanni Paganelli (Meldola, Italy)

15:45 – 16:15 Coffee/Tea, Visit of Trade Exhibition


SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

FridayD

ecember 13, 2019

16:15 – 17:30 Session III Chairpersons: Markus Luster (Marburg, Germany)

Partha Choudhary (Delhi, India)

FES IN THERANOSTICS OF RECURRENT BREAST CANCER Jean-Noël Talbot (Paris, France)

PSMA TARGETED THERAPY WITH RADIOLABELED ANTIBODIES: CORNELL EXPERIENCE

Shankar Vallabhajosula (New York, USA)

Chairpersons: Hossein Jadvar (Los Angeles, USA) Madhukar Thakur (Philadelphia, USA)

THE PSMA STORY – FROM THE SHADOWS TO STORM URO-ONCOLOGY

Martin Pomper (Baltimore, USA)

225Ac PSMA IN METASTATIC PROSTATE CANCER WITHOUT PREVIOUS CHEMOTHERAPY

Mike Sathekge (Pretoria, South Africa)

Satu

rday

Dec

embe

r 14

, 201

9

SATURDAY, DECEMBER 14, 2019

08:00 – 10:30 Session IV Chairpersons: Kjell Öberg (Uppsala, Sweden)

Edward Wolin (New York, USA) Kalevi Kairemo Helsinki (Finland)

COMBINING SURGERY WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY – A STEP FORWARD IN TREATMENT OF ADVANCED NEUROENDOCRINE TUMORS

Andrea Frilling (London, UK)

INSPIRED BY…. Daniel Kämmerer (Bad Berka, Germany)

MODE OF ACTION OF PRRT WITH 177LU-DOTATOC – EMPHASIS ON THE IMMUNOLOGICAL ASPECTS

Cees van Echteld (Dresden Germany)

THERANOSTIC RADIOPEPTIDES IN NUCLEAR ONCOLOGY: DESIGN, PRECLINICAL SCREENING AND CLINICAL TRANSLATION

Theodosia Maina-Nock (Athens, Greece)

Chairpersons: Frans Corstens (Nijmegen, The Netherlands) Dieter Hörsch (Bad Berka, Germany) Ken Herrmann (Essen, Germany)

SOMATOSTATIN RECEPTOR EXPRESSION DETECTED BY IMMUNOHISTOCHEMISTRY

Günter Klöppel (Munich, Germany)

OPTIMIZING TARGETED TUMOR THERAPY IN THE CONTEXT OF TME AND MOLECULAR BACKGROUND – THERANOSTICAL ONCOLOGY AT ITS BEST

Patricia Grabowski (Berlin, Germany)

THE LUGENIUM TRIPTYCH: ODE TO A THERANOSTICS TRANSCRIPTOME

Lisa Bodei (New York, USA)


SaturdayD

ecember 14, 2019

SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

Satu

rday

Dec

embe

r 14

, 201

9

10:30 – 11:00 Coffee/Tea, Visit of Trade Exhibition

11:00 – 13:30 Session V Chairpersons: Helmut Mäcke (Freiburg, Germany)

Hakim Bouterfa (Würzburg, Germany) Chen Liu (Beijing, China)

MILESTONES OF THERAPIES IN NEN Marianne Pavel (Erlangen, Germany)

THERANOSTICS WITH SOMATOSTATIN RECEPTOR ANTAGONISTS

Damian Wild (Basel, Switzerland)

REAL WORLD DATA FROM THERANOSTIC CLINICAL CENTRES OF EXCELLENCE DEFINE ACHIEVABLE ONCOLOGY PRACTICE OUTCOMES WORLDWIDE

J. Harvey Turner (Perth, Australia)

PRECISION ONCOLOGY: CHALLENGING THE CLASSICAL STATISTICAL EVIDENCE-BASED MEDICINE Vikas Prasad (Ulm, Germany)

Chairpersons: John Buscombe (Cambridge, UK) Seigo Kinuya (Kanazawa, Japan) Michael Kreißl (Magdeburg, Germany)

DOSIMETRY AND RADIOBIOLOGY IN PRRT: WHERE ARE WE TODAY

Marta Cremonesi (Milano, Italy)

LU-177 DOSIMETRY – THE BAD BERKA EXPERIENCE Christiane Schuchardt (Bad Berka)

PRECISION THERANOSTICS...“TO D OR NOT TO D“ Richard Wahl (St. Louis, USA)

13:30 – 14:30 Lunch, Visit of Trade Exhibition

14:30 – 16:30 Session VI Chairpersons: John Prior (Lausanne, Switzerland)

Zhi Yang (Beijing, China) Horacio Amaral (Santiago de Chile, Chile)

SEEING IS BELIEVING: TOTAL-BODY POSITRON EMISSION TOMOGRAPHY

Simon Cherry (Davis, USA)

PURPOSE-BUILT MEDICAL AI PLATFORM LIGHTING THE WAY TO INTELLIGENCE-BASED PRECISION MEDICINE

Anthony Chang (Grand Rapids, USA)

Chairpersons: Manfred Fischer, (Kassel, Germany) Markus Essler (Bonn, Germany) Klemens Scheidhauer (Munich, Germany)

PRRT OF NEN: SAFETY, SURVIVAL, AND OUTCOME PREDICTORS IN A LARGE COHORT OF PATIENTS WITH HIGH-GRADE, OTHER SSTR-EXPRESSING TUMORS AND RARE CONDITIONS

Jingjing Zhang (Philadelphia, USA)

PSMA RADIOLIGAND THERAPY (PRLT) – IS THE EARLIER, THE BETTER?

Harshad Kulkarni (Bad Berka, Germany)

INTRA-ARTERIAL PRRT OF SSTR-POSITIVE LIVER METASTASES – THE BAD BERKA EXPERIENCE

Aviral Singh (Bad Berka, Germany)

RANDOM WALK IN NUCLEAR MEDICINE – HOW A CHANCE MEETING CHANGED THE COURSE OF NET PATIENT CARE IN THE US

Josh Mailman (San Francisco, USA)

16:30 Closing Remarks


clovisoncology.com

ADVANCING THE FIGHTAGAINST CANCER

LIST OF SPONSORS

Double Platinum Sponsor

BAMF Health15 Michigan Street NE49503 Grand Rapids, USAwww.BamfHealth.com

Platinum Sponsors

3B Pharmaceuticals GmbHMagnusstraße 1112489 Berlin, Germany www.3b-pharma.com

ITM Isotopen Technologien München AGSchleissheimer Straße 9185748 Garching, Germanywww.itm.ag

Clovis Oncology5500 Flatiron PkwyBoulder, CO 80301, USAwww.clovisoncology.com

SINOTAUSinotau Pharmaceutical Group5th Floor, 9 Building, 8th Life Park, Life Science Park102206 Beijing, Chinawww.sinotau.com


LIST OF SPONSORS LIST OF SPONSORS

Silver Sponsors

ABX-CRO advanced pharmaceuticalservices ForschungsgesellschaftBlasewitzer Straße 78-8001307 Dresden, Germanywww.abx-cro.com

SCINTOMICSLindach 482256 Fürstenfeldbruck, Germanywww.scintomics.com

Advanced Accelerator Applications Germany GmbH, a Novartis companySaime Genc Ring 1853121 Bonn, Germanywww.adacap.com

Siemens Healthcare GmbHHenkestraße 12791052 Erlangen, Germanywww.siemens-healthineers.com

Telix PharmaceuticalsSuite 401/55 Flemington RoadNorth Melbourne VIC 3051, Australiawww.telixpharma.com

Diamond Sponsors

United Imaging Healthcare Technology Group Co. Ltd.2258 Chengbei Rd.,Jiading District, Shanghaiwww.united-imaging.com

Gold Sponsors

MAP Medical Technologies OyElementtitie 27 FI-41160 Tikkakoski, Finlandwww.mapmedical.fi

Molecular Targeting Technologies, Inc833 Lincoln Ave., Unit 9, West Chester, Pennsylvania 19380, USAwww.mtarget.com


LIST OF SPONSORS

Bronze Sponsors

Cardinal Health7000 Cardinal PlaceDublin, OH 43017, USA

CheMatech2 rue Pauline Kergomard21000 Dijon Francewww.chematech-mdt.com

Eckert & Ziegler Eurotope GmbH Robert-Rössle-Straße 1013125 Berlin, Germanywww.radiopharma.com

IBA RadioPharma SolutionsChemin du Cyclotron, 31348 Louvain-la-Neuve, Belgiumwww.iba-radiopharmasolutions.com

Hermes Medical Solutions ABStrandbergsgatan 1611251 Stockholm, Swedenwww.hermesmedical.com

MEDISO GmbHSteinfurter Straße 6648149 Münster, Germanywww.mediso.de

National Centre for Nuclear Research Radioisotope Centre POLATOM Andrzej Soltan 7 05-400 Otwock, Poland www. polatom.pl

Pent ixaPharmPentixaPharm GmbHBismarckstr.1397080 Würzburg, Germanywww.1717lsv.com

Sponsors

Advanced Innovative Partners, Inc.7947 Brookside Ct.33467, Lake Worth, Fl., USAwww.AdvancedInnovativePartners.com

ROTOP Pharmaka GmbHBautzner Landstr. 400 01328 Dresden, Germanywww.rotop-pharmaka.de

GE Healthcare (GEMS PET Systems AS)Husbyborgsvägen 1 | SE-752 28 Uppsala, Swedenwww.gehealthcare.com

TRASISRue Gilles Magnée, 90 4430 Ans, Belgiumwww.trasis.com

small details create the big picture

isotopia Molecular ImagingAlexander yanai 3949277, petach tikva, Israelwww.isotopia.co.il

LIST OF SPONSORS

THERANOSTICS / Precision Oncology26

EXHIBITORS

ICPO Holding gGmbHBanneggstr. 57 88214 Ravensburg, Germanyhttps://icpo.foundation

The Oncidium Foundationc/o SCK-CENAvenue Herrmann-Debroux, 401160 Auderghem, Belgiumwww.oncidium-life.org

Netzwerk Neuroendokrine Tumoren (NeT) e.V.Wörnitzstr. 115a90449 Nürnberg, GermanyInternet: www.netzwerk-net.de


TRANSPARENCY REQUIREMENTS

IMPRESSUM177Lu-EBTATE targeting somatostatin receptorsClinical studies in 33 patients with gastroenteropancreatic neuroendocrine tumors (NET) showed safety and improved efficacy.

MOLECULAR TARGETING TECHNOLOGIES, INC. Translating novel radiopharmaceuticals into tomorrow’s medicine

177Lu-EBRGD targeting αvβ3 overexpressing tumors In development for Glioblastoma Multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC).

Best-in-class targeted radiotherapeutics (TRT) incorporating Evans Blue (EB) to prolong circulation half-life and increase tumor accumulation and targeting.

EBTATE: Single Injections (3 months after 19.5 mCi). Reduced primary tumor by 53% & liver metastasis by 45%

Molecular Targeting Technologies, Inc. (www.mtarget.com) is a privately held biotechnology company acquiring and developing robust technologies for treatment of diseases. Contact: Chris Pak- [email protected]

Transparency requirements in accordance with FSA Code and guidelines of AKG and BVMed

Regarding the membership of the following partners of the industry in the AKG e.V. (pharmaceuticals and cooperation in the health care sector), BVMed e.V. (Ger-man Medical Technology Association) FSA e.V. (voluntary self-regulation for the pharmaceutical industry), or because the companies have approved the publica-tion, we inform you about the financial assistance for the International Symposium on the Occasion of the 20th Anniversary of Molecular Radiotherapy Bad Berka and Inauguration of the ICPO Foundation.

Advanced Accelerator Applications Germany GmbH 5.000,00 € for a sponsorship „Silver Sponsor” Clovis Oncology Inc. 25.000,00 € for a sponsorship „Platinum Sponsor”

ROTOP Pharmaka GmbH 2.000,00 € for a sponsorship „Sponsor“

Siemens Healthcare GmbH 5.000,00 € for a sponsorship „Silver Sponsor”

RADIOPHARMACEUTICALS FOR THERAGNOSTICS

Congress ChairmanProf. Dr. Richard P. BaumICPO Foundation / ICPO Holding gGmbHHumboltstrasse 2965189 WiesbadenTelefon ICPO +49 (0) 611-341 486 [email protected] www.icpo.foundation

Copy deadline6. December 2019


FESTSCHRIFT AND SCRAP BOOK

CIRCLE of SCIENCE A journey through time of

molecular medicine

Prof. Dr. Richard P. BaumJulitta Rück-Baum

The Festschrift, edited by R.P. Baum and V. Prasad (“Beyond Becquerel and Biology to Radio-molecular Precision Oncology”) in honor of Richard P. Baum will be published by Springer (online and printed version) in 2020 and contain contributions from world renowned authors and scientists.

The Festschrift will be a treasure for future precision oncologists containing scientific commenta-ries, reviews and some though provoking novel scientific ideas.

Festschrift in Honor of

Richard P. Baum

2020

Beyond Becquerel and Biology to Radiomolecular

Precision Oncology

Developing Targeted Radionuclide Therapies in Precision Oncology.

www.itm.ag

PRECISELY FOR ME.

Dedicated to giving cancer patients better answers than “maybe”.

191121_ITM_Az_148x210_E_02_RZ.indd 1191121_ITM_Az_148x210_E_02_RZ.indd 1 22.11.19 15:1022.11.19 15:10

BAMF Health is achieving AI-enabled intelligence-based precision medicine through molecular imaging & theranostics.

We partner with leading medical centers around the world to build:

• Cyclotron Radiopharmacies • Medical AI Platform

• Theranostics Clinics • Clinical Trial Platform

www.bamfhealth.com

Programme Guide · Programme Guide. THERANOSTICS Precision Oncology 3 WELCOME MESSAGE radioisotopes...

Documents

Transcript of Programme Guide · Programme Guide. THERANOSTICS Precision Oncology 3 WELCOME MESSAGE radioisotopes...